John Matulsky

Overview

Independent biologics consultant advising on capex strategy and manufacturing due diligence, with prior CMO leadership at Lonza (US and Singapore scale-up), Sanofi, Catalent, and Cytiva (formerly GE Life Sciences). John Matulsky set up an independent consultancy approximately one year before the panel, focusing on manufacturing due diligence and capex strategy, after decades in CMO roles including Lonza's large-scale cell culture expansion into the US and Singapore, capex leadership at Sanofi Biologics, and drug product manufacturing at Catalent. John Matulsky identifies human capital — specifically the mid-level layer of process engineers and QC supervisors — as the single biggest manufacturing constraint, given unprecedented US biomanufacturing investment in locations like North Carolina (six or seven major announcements) and Indiana. (Segment 3 (10:00-15:00))